China Resources Double-Crane Pharmaceutical (SHA:600062) passed the good manufacturing practice compliance inspection for its sugammadex sodium injection.
Sugammadex sodium can be used to treat neuromuscular blockade induced by rocuronium or vecuronium, according to a Wednesday filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments